✦ LIBER ✦

Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study

✍ Scribed by L. PEYRIN-BIROULET; C. LACLOTTE; M.-A. BIGARD

Book ID: 108604886
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 482 KB
Volume: 25
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2007.03254.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adalimumab for Crohn’s disease with into

Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience

✍ A. OUSSALAH; A. BABOURI; J.-B. CHEVAUX; L. STANCU; I. TROUILLOUD; M. BENSENANE; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB

Efficacy and safety of short-term adalim

Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial

✍ J. HINOJOSA; F. GOMOLLÓN; S. GARCÍA; G. BASTIDA; J. L. CABRIADA; C. SARO; D. CEB 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 557 KB

Open-label study of adalimumab in patien

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab

✍ Waqqas Afif; Jonathan A. Leighton; Stephen B. Hanauer; Edward V. Loftus Jr; Will 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Background: The aim of this study was to assess the clinical benefit and tolerability of adalimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF), in patients with ulcerative colitis (UC). Methods: Patients with active UC, including those who had lost response or developed

Long-term outcome of adalimumab therapy

Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience

✍ A. OUSSALAH; C. LACLOTTE; J.-B. CHEVAUX; M. BENSENANE; A. BABOURI; A.-A. SERRE; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

C-reactive protein, an indicator for mai

C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I

✍ W. Reinisch; Y. Wang; B. J. Oddens; R. Link 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB